Bristol Myers Squibb's admilparant met the Phase III ALOFT-IPF primary endpoint, showing significant FVC gains in pulmonary ...
Icotrokinra (Icotyde) sustained PASI 90 in at least 72% of plaque psoriasis patients through two years in Phase III ICONIC-LEAD. Read the full results.
EU application is back under EMA review for EGFR-mutated NSCLC. Find out what this resubmission means for patients today.
FDA approves Hovilpri (pritelivir) for herpes lesions resistant to acyclovir, valacyclovir, or famciclovir in ...
A JAMA Phase III trial finds nicotinamide riboside worsens outcomes vs placebo in early Parkinson's. Read the full NOPARK ...
FDA approves Teva's Weltruza, the first once-monthly subcutaneous olanzapine LAI for adult schizophrenia. Read what it means ...
Chai Discovery and GSK announce a collaboration giving GSK access to protein folding and design AI models after wet-lab ...
RougeTx raised $58 million in Series A funding to advance its HHT treatment toward clinical development. See who backed the ...
The TAURUS-1980 Phase I study has dosed its first participants, testing AV-1980R as a preventive tau vaccine. Read what researchers will assess next.
A Dutch court barred Merck from making or selling Keytruda SC in eight European markets, ruling in Halozyme’s patent dispute. Read what the order means now.
SurVaxM missed its overall survival endpoint in glioblastoma, but patients 65 and younger saw a significant benefit. Read the trial results and context.
Biohub, DOE, NIH, Google DeepMind, Meta and research partners pledge $1.8B for an open-source AI virtual cell. Read more: Explore the initiative's goals.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results